This trial will test whether adding savolitinib to osimertinib can help patients with EGFRm+ and MET+ NSCLC that has progressed after osimertinib treatment.
1 Primary · 18 Secondary · Reporting Duration: Blood samples collected at Screening within 28 days before the first dose of study treatment; on day of first dose of study treatment; at discontinuation 7 days after last dose of study treatment. (One cycle = 28 days)
Awards & Highlights
2 Treatment Groups
osimertinib + savolitinib
1 of 2
placebo + savolitinib
1 of 2
360 Total Participants · 2 Treatment Groups
Primary Treatment: osimertinib · Has Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
- Schmid, Sabine, Martin Früh, and Solange Peters. 2020. “Targeting MET in EGFR Resistance in Non-small-cell Lung Cancer—ready for Daily Practice?”. The Lancet Oncology. Elsevier BV. doi:10.1016/s1470-2045(19)30859-9.
- Schmid S, Fruh M, Peters S. Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice? Lancet Oncol. 2020 Mar;21(3):320-322. doi: 10.1016/S1470-2045(19)30859-9. Epub 2020 Feb 3. No abstract available.
- 2019. "Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03778229.
Frequently Asked Questions
How many healthcare facilities are hosting this research experiment?
"This trial is currently available at 13 medical locations, including Toronto, La Jolla and Brooklyn. To minimize travel requirements for participants, it's best to select the clinic nearest your residence." - Anonymous Online Contributor
Has osimertinib received the regulatory green light from the FDA?
"Our team's appraisal of osimertinib's safety yielded a rating of 2, as data exists to back up its protection but it has yet to be determined if the medication is effective." - Anonymous Online Contributor
Are there still open slots available for participants in this research endeavor?
"Affirmative, according to the information posted on clinicaltrials.gov this medical trial is accepting patients. The study debuted on September 1st 2019 and was last modified November 28th 2022. Recruitment of 360 individuals from 13 sites is required for completion of the trial." - Anonymous Online Contributor
Have there been any precedential investigations related to osimertinib?
"Osimertinib was first trialed in 2013 at Research Site, and now boasts 2734 completed studies. Of the 112 active investigations of this medication, many are situated around Toronto, Ontario." - Anonymous Online Contributor
Is this a pioneering trial that is attempting to break new ground?
"Currently, 112 clinical trials for osimertinib are being conducted in 1080 cities and 51 countries. Since its first trial sponsored by AstraZeneca commenced in 2013 with 603 participants, 2734 studies have been successfully completed." - Anonymous Online Contributor
How many individuals are joining this research endeavor?
"Affirmative. Information available on clinicaltrials.gov indicates that this trial is actively enrolling, with the first listing posted on September 1st 2019 and most recently updated in November 28th 2022. The research project aims to recruit 360 patients from 13 different medical centres." - Anonymous Online Contributor